Overview

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, 2 arm randomized crossover study. Subjects will be assigned to either active agent or placebo and then crossover to the other arm. This study is designed to evaluate whether Fycompa improves the quality of life in patients with small fiber neuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
PNA Center for Neurological Research
Collaborator:
Eisai Inc.
Treatments:
Excitatory Amino Acid Antagonists